Aron Liaw, MD
Urology · Dearborn, MINPI 1962760595
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Axonics, Inc. at 24.6% of the total.
Across 194 payments — averaging $92.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$4K
- Intuitive Surgical$4K
- Coloplast$3K
- Medtronic$2K
- Boston Scientific$778
- Procept Biorobotics Corporation$298
- plus $3K from 32 others
What the payments were for
- Travel & lodging$6,26435%
- Food & beverage$8,57648%
- Education$3,18318%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 43 | $4,432 |
| Intuitive Surgical | 6 | $4,244 |
| Coloplast | 32 | $3,423 |
| Medtronic | 18 | $1,863 |
| Boston Scientific | 17 | $778 |
| Procept Biorobotics Corporation | 4 | $298 |
| Urogen Pharma, Inc. | 3 | $253 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $187 |
| UCB, Inc. | 4 | $182 |
| Valencia Technologies Corporation | 3 | $175 |
| Mimedx Group, Inc. | 1 | $173 |
| Laborie Medical Technologies Corp. | 5 | $157 |
| Calyxo, Inc. | 1 | $156 |
| 180 Medical, Inc. | 6 | $156 |
| AbbVie(2 entities) | 9 | $155 |
| Biotissue Holdings Inc. | 1 | $141 |
| Johnson & Johnson(2 entities) | 4 | $135 |
| Rochester Medical Corporation | 2 | $134 |
| Myriad Genetic Laboratories, Inc. | 1 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $118 |
| Ferring Pharmaceuticals Inc. | 1 | $107 |
| Antares Pharma, Inc. | 2 | $100 |
| Smith+Nephew | 3 | $88 |
| Teleflex LLC | 4 | $74 |
| Merck | 3 | $53 |
| Olympus America Inc. | 3 | $51 |
| Dentsply IH Inc. | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| AstraZeneca | 1 | $22 |
| Convatec Inc. | 1 | $21 |
| Immunitybio, Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Ambu Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$3,000
- TITAN$2,323
- Axonics$2,270
- Bulkamid$2,056
- Da Vinci Surgical System$1,227
- Axonics r-SNM System$1,216
- ALTAVIVA$1,033
- INTERSTIM$402
- CVAC Aspiration System$156
- Prolaris$133
- Bard Urinary Drainage Bag$125
- AQUABEAM SYSTEM$124
- AquaBeam Robotic System$123
- JELMYTO$121
- ZUSDURI$111
- eCoin Device Kit$109
- ADSTILADRIN$107
How this compares
$18,023 in reported general payments places this provider in the 85th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 75 | $48,341 |
| GemtesaVibegron | 12 | $11,507 |
| Mirabegron ErMirabegron | 21 | $9,491 |
| Estradiol | 99 | $6,636 |
| Tamsulosin Hcl | 158 | $1,947 |
| Oxybutynin Chloride ErOxybutynin Chloride | 96 | $1,392 |
| Methenamine Hippurate | 16 | $1,235 |
| Finasteride | 123 | $988 |
| Clobetasol Propionate | 19 | $422 |
| Oxybutynin Chloride | 17 | $417 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $154 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $99 |
| Levofloxacin | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $17 | $48,34175 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $36 | $11,50712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 urology providers in Michigan.
Other urology in Dearborn
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Richard BennettRoyal Oak$361K
- Ryan NelsonUtica$296K
- Casey DauwAnn Arbor$188K
- Aram LoebDetroit$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.